New hope for tough leukemia: MK-1045 takes on standard therapy

NCT ID NCT07570173

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen May 11, 2026 · Last updated Jun 11, 2026 · Updated 10 times

Summary

This study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal is to see if MK-1045 leads to more complete remissions and longer survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Haddasah Medical Center ( Site 0900)
RECRUITING

Jerusalem, 9112001, Israel

Contact Phone: •••-•••-••••
Rambam Health Care Campus ( Site 0903)
RECRUITING

Haifa, 3109601, Israel

Contact Phone: •••-•••-••••
Sheba Medical Center ( Site 0902)
RECRUITING

Ramat Gan, 5265601, Israel

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA